Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Baylor College of Medicine
Goethe University
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
University College, London
Universitätsklinikum Hamburg-Eppendorf
Wake Forest University Health Sciences
University of Ulm
Memorial Sloan Kettering Cancer Center
Children's Mercy Hospital Kansas City
Goethe University
Goethe University
H. Lee Moffitt Cancer Center and Research Institute
Massachusetts General Hospital
St. Jude Children's Research Hospital
Goethe University
St. Jude Children's Research Hospital
University Hospital Schleswig-Holstein
Gruppo Italiano Malattie EMatologiche dell'Adulto
St. Jude Children's Research Hospital
UNICANCER
St. Jude Children's Research Hospital
University of Ulm
Massachusetts General Hospital
PETHEMA Foundation
PETHEMA Foundation
M.D. Anderson Cancer Center
University of California, San Francisco
Gruppo Italiano Malattie EMatologiche dell'Adulto
Ohio State University Comprehensive Cancer Center
French Innovative Leukemia Organisation
Ludwig-Maximilians - University of Munich
Hospital Israelita Albert Einstein
Alliance for Clinical Trials in Oncology
University of Ulm
Memorial Sloan Kettering Cancer Center
PETHEMA Foundation
St. Jude Children's Research Hospital
University Health Network, Toronto
The Catholic University of Korea
Associazione Italiana Ematologia Oncologia Pediatrica
Rutgers, The State University of New Jersey
Acute Leukemia French Association
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University Hospital Schleswig-Holstein
The Cleveland Clinic